Viking Therapeutics (VKTX) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Viking Therapeutic (VKTX) PT Lowered to $20 at Maxim Group, Remains Bullish
March 14, 2019 7:35 AM EDTMaxim Group analyst Jason McCarthy lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $20.00 (from $28.00) while maintaining a Buy rating following Q4.
Viking reported 4Q18 with a net loss of ($5.6M) and ended the year with $302M in cash on the balance sheet. Over the course of 2018, the NASH space continued to deliver positive data, in... More